News | May 02, 2026
FDA renews IQOS “reduced-risk” status backing PMI’s smoke-free strategy in regulatory win
The renewal covers two versions of the IQOS device and three HEETS tobacco variants
The renewal covers two versions of the IQOS device and three HEETS tobacco variants
On his visit to NIPER Mohali, union health minister vreviews biopharma research initiatives and calls for stronger industry collaboration and commercialization focus
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
Minimally invasive laser-based procedure restores blood flow in complex arterial blockage, enables next-day discharge and improved mobility
Subscribe To Our Newsletter & Stay Updated
